Tuberculosis 2015: Burden, challenges and strategy for control and elimination

Infectious Disease Reports

Volumn 8, Issue 2, 2016, Pages 33-37

  Raviglione, Mario ^a   Sulis, Giorgia ^b  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Elimination; End tuberculosis strategy; Tuberculosis control; Tuberculosis epidemiology

Indexed keywords

ANTIRETROVIRUS AGENT; BEDAQUILINE; DELAMANID;

ARTICLE; BACTERIAL TRANSMISSION; CLINICAL RESEARCH; DEATH; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HEALTH CARE ACCESS; HEALTH CARE FINANCING; HEALTH INSURANCE; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; PREVALENCE; SOCIAL DETERMINANTS OF HEALTH; SUSTAINABLE DEVELOPMENT; TUBERCULOSIS; TUBERCULOSIS CONTROL; WORLD HEALTH ORGANIZATION;

EID: 84992700365     PISSN: None     EISSN: 20367449     Source Type: Journal    
DOI: 10.4081/idr.2016.6570     Document Type: Article

References (29)

1. Lacerda SNB, de Abreu Temoteo RC, Monteiro de Figueiredo TMR, et al. Individual and social vulnerabilities upon acquiring tuberculosis: a literature systematic review. Int Arch Med 2014;7:35.
2. World Health Organization. Global tuberculosis report 2015. Available from: http://apps.who.int/iris/bitstream/10665/19 1102/1/9789241565059_eng.pdf?ua=1. Accessed: October 2015.
3. Kerschberger B, Hilderbrand K, Boulle AM, et al. The effect of complete integration of HIV and TB services on time to initiation of antiretroviral therapy: a before-after study. PLoS One 2012;7:e46988.
4. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2013. Available from: http://www.who.int/iris/bitstream/10665/85 321/1/9789241505727_eng.pdf?ua=1. Accessed: October 2015.
5. Sotgiu G, Matteelli A, Migliori GB. Diabetes and tuberculosis: what else beyond? Behaviour and information technology. Int J Tuberc Lung Dis 2015;19: 1127-8.
6. United Nations General Assembly. United Nations Millennium Declaration, Resolution Adopted by the General Assembly, 2000, A/RES/55/2. Available from: http://www.refworld.org/docid/3b00f4ea3.html. Accessed: October 2015.
7. Lomazzi M, Borisch B, Laaser U. The millennium development goals: experiences, achievements and what's next. Glob Health Action 2014;7:2369.
8. Herbert N, George A, Baroness Mashamof I, et al. World TB Day 2014: finding the missing 3 million. Lancet 2014;383:1016-8.
9. Falzon D, Mirzayev F, Wares F, et al. Multidrug-resistant tuberculosis around the world: what progress has been made? Eur Respir J 2015;45:150-60.
10. World Health Organization. WHO policy on TB/HIV collaborative activities: guidelines for national programmes and other stakeholders. 2012. Available from: http://apps.who.int/iris/bitstream/10665/44 789/1/9789241503006_eng.pdf?ua=1&ua=1. Accessed: October 2015.
11. Gupta S, Granich R, Date A, et al. Review of policy and status of implementation of collaborative HIV-TB activities in 23 highburden countries. Int J Tuberc Lung Dis 2014;18:1149-58.
12. Murray CJ. Shifting to sustainable development goals. Implications for global health. N Engl J Med 2015;373:1390-3.
13. Hill PS, Buse K, Brolan CE, Ooms G. How can health remain central post-2015 in a sustainable development paradigm? Global Health 2014;10:18.
14. World Health Organization. Resolution WHA67/11: Global strategy and targets for tuberculosis prevention, care and control after 2015. 2014. Available from: http://apps.who.int/gb/ebwha/pdf_files/WH A67/A67_11-en.pdf.
15. Touraine M, Gröhe H, Coffie RG, et al. Universal health coverage and the post-2015 agenda. Lancet 2014;384:1161-2.
16. Gupta V, Kerry VB, Goosby E, Yates R. Politics and universal health coverage. The post-2015 global health agenda. N Engl J Med 2015;373:1189-92.
17. Uplekar M, Weil D, Lonnroth K, et al. WHO's new end TB strategy. Lancet 2015;385:1799-801.
18. Lönnroth K, Glaziou P, Weil D, et al. Beyond UHC: monitoring health and social protection coverage in the context of tuberculosis care and prevention. PLoS Med 2014;11:e1001693.
19. Schito M, Maeurer M, Kim P, et al. Translating the tuberculosis research agenda: much accomplished, but much more to be done. Clin Infect Dis 2015;61:S95-S101.
20. World Health Organization. Global consultation on research for TB elimination. 2014. Available from: http://www.who.int/tb/features_archive/re searchforTBelimination_meeting/en/. Accessed: October 2015.
21. Walker TM, Kohl TA, Omar SV, et al. Wholegenome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study. Lancet Infect Dis 2015;15:1193-202.
22. Evangelopoulos D, McHugh TD. Improving the tuberculosis drug development pipeline. Chem Biol Drug Des 2015;86:951-60.
23. Zumla AI, Gillespie SH, Hoelscher M, et al. New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects. Lancet Infect Dis 2014;14:327-40.
24. Kakkar AK, Dahiya N. Bedaquiline for the treatment of resistant tuberculosis: promises and pitfalls. Tuberculosis (Edinb) 2014;94:357-62.
25. Gupta R, Geiter LJ, Wells CD, et al. Delamanid for extensively drug-resistant tuberculosis. N Engl J Med 2015;373:291-2.
26. Sotgiu G, Pontali E, Centis R, et al. Delamanid (OPC-67683) for treatment of multi-drug-resistant tuberculosis. Expert Rev Anti Infect Ther 2015;13:305-15.
27. Kaufmann SH, Lange C, Rao M, et al. Progress in tuberculosis vaccine development and host-directed therapies: a state of the art review. Lancet Respir Med 2014;2:301-20.
28. Wilkie ME, McShane H. TB vaccine development: where are we and why is it so difficult? Thorax 2015;70:299-301.
29. Moliva JI, Turner J, Torrelles JB. Prospects in Mycobacterium bovis Bacille Calmette et Guérin (BCG) vaccine diversity and delivery: why does BCG fail to protect against tuberculosis? Vaccine 2015; 33:5035-41.